Search Results 1461-1470 of 21307 for Informed consent

1. Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers - Mayo Clinic

   Patients must sign an Informed Consent and Authorization indicating that they are aware of the investigational nature of this study and the known risks involved ...

2. Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer - Mayo Clinic

   Ability to provide informed written consent. Exclusion Criteria: Radiological- or pathologically-confirmed seminal vesicle invasion, lymph node involvement ...

3. Evaluation Of Dual Therapy With Dabigatran Versus Triple Therapy With Warfarin In Patients With Atrial Fibrillation That Undergo A Percutaneous Coronary Intervention With Stenting (REDUAL-PCI) - Mayo Clinic

   The patient must be able to give informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local ...

4. Senescence in Chronic Kidney Disease - Clinical Trials

   Inability to give informed consent. Uncontrolled systemic lupus erythematosus. Uncontrolled pleural/pericardial effusions or ascites. New invasive cancer ...

5. A Study Of RAP-219 In Refractory Focal Onset Seizures - Mayo Clinic

   Able and willing to provide written informed consent to participate in the study in accordance with International Council for Harmonisation-Good Clinical ...

6. Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Sign an informed consent; Age ≥18 years; Diagnosis of relapsed or refractory lymphoid malignancy for which there are no available therapies; Discontinuation ...

7. An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... informed consent through 90 days after the last dose of study therapy; OR; Agree to practice true abstinence, when this is in line with the preferred and ...

8. A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Mayo Clinic

   Patient must have provided study specific informed consent prior to study entry ... inform her treating physician immediately; Women of child-bearing ...

9. Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers - Mayo Clinic

   All participants will be >18 years of age and will provide informed consent. Exclusion criteria for cases: Patients with history of esophagectomy or mucosal ...

10. Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine - Mayo Clinic

    Patient must signed an informed consent form. Exclusion Criteria: Previous participation in a clinical study of IV or oral rigosertib. Anemia due to factors ...